LL-37 Side Effects: Safety Signals and Warnings
LL-37 safety concerns are compound-specific. The main listed side effects are Possible injection site reactions, May cause local inflammation at high concentrations, and Hemolytic activity at very high concentrations. The main warning signals are Early-stage research peptide only, Can be pro-inflammatory at high concentrations, and May exacerbate autoimmune conditions.
Direct Answer
Evidence for LL-37 is too preliminary to support a research protocol with confidence. Human data is limited to small wound-healing and topical studies; no Phase 2/3 trials exist for systemic use. Of the Immune Support compounds, thymosin alpha-1 (thymosin-alpha-1) has a substantially stronger evidence base as a starting point.
- Evidence grade
- Level C
- Research status
- Phase 1
- Category
- Immune Support
- Best for
- Antimicrobial peptide research, wound healing (topical), innate immunity mechanistic studies
Reported Side Effects
- Possible injection site reactions
- May cause local inflammation at high concentrations
- Hemolytic activity at very high concentrations
- Limited human safety data
Warnings
- Early-stage research peptide only
- Can be pro-inflammatory at high concentrations
- May exacerbate autoimmune conditions
- Rapidly degraded in vivo, limiting therapeutic utility
- No approved human dosing guidelines
Known or Plausible Interactions
- Vitamin D (upregulates LL-37 production)
- Immunosuppressants (may counteract effects)
- Antibiotics (potential synergy against resistant bacteria)
Regulatory Context
LL-37 is a research peptide not approved for clinical use. Available for research purposes. Not a controlled substance. Active area of pharmaceutical development with modified analogs in clinical trials.
Evidence Snapshot
| Evidence grade | Level C |
|---|---|
| Research status | Phase 1 |
| Best supported outcomes | Antimicrobial Activity (Level B), Immune Modulation (Level C), Wound Healing Support (Level C), and Anti-Biofilm (Level C) |
| Primary citation count | 2 |
| Last reviewed | 2026-04-04 |
Related Guides
How to Cite This Page
ExaminePeptides. "LL-37 Side Effects: Safety Signals and Warnings." Last reviewed 2026-04-04. https://examinepeptides.com/answers/ll-37-side-effects-safety/
This static answer page is built for fast indexing and direct citation. It summarizes the matching full evidence review and links back to primary sources where the source database includes them.